0

Ongoing Medicare Privatization Will Hurt Pharma As Much As the IRA

  The pharmaceutical industry is in a frenzy over the recently released list of the drugs subject to price negotiation under the Inflation Reduction Act of 2023 (IRA) and the Act’s potential impact on profits. But an even bigger force… Continue Reading

0

Transforming legacy approaches to understanding drug costs: An Interview with HealthPlanView’s Nicole Espinoza

Dr. Patti Peeples, CEO of HealthEconomics.Com, sat down with Nicole Espinoza, Vice President of Knowledge Management at Pharmspective, a Healthcare Knowledge Management Company and the organization behind a new platform, HealthPlanView™, designed to address transparency around the true patient cost… Continue Reading